Regulation of cytochrome P450 expression by Ras- and β-catenin-dependent signaling

Current Drug Metabolism

Volumn 10, Issue 2, 2009, Pages 138-158

  Braeuning, Albert ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Catenin; Cytochrome P450; Ha Ras; Liver; Liver tumor; MAP kinase; Metabolic zonation; WNT

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AROMATIC HYDROCARBON RECEPTOR; BETA CATENIN; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 2C11; CYTOCHROME P450 2E1; EPIDERMAL GROWTH FACTOR; ERBSTATIN; GENISTEIN; GLUCAGON; HEPATOCYTE NUCLEAR FACTOR; INSULIN; INTERLEUKIN 1; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PREGNANE X RECEPTOR; RAS PROTEIN; RIFAMPICIN; SCATTER FACTOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR ALPHA; UNINDEXED DRUG; VANADATE SODIUM; WNT PROTEIN; XENOBIOTIC AGENT;

CARCINOGENESIS; CELL PROLIFERATION; COLON ADENOMA; COLORECTAL CARCINOMA; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME REGULATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE REPRESSION; HORMONE METABOLISM; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; XENOBIOTIC METABOLISM;

ANIMALS; BETA CATENIN; CYTOCHROME P-450 ENZYME SYSTEM; ENZYMES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENES, RAS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; WNT PROTEINS; XENOBIOTICS;

EID: 65549136561     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009787522160     Document Type: Review

References (146)

1. Benhamouche, S.; Decaens, T.; Godard, C.; Chambrey, R.; Rickman, D.S.; Moinard, C.; Vasseur-Cognet, M.; Kuo, C.J.; Kahn, A.; Perret, C.; Colnot, S. Apc tumor suppressor gene is the "zonation-keeper" of mouse liver. Dev. Cell, 2006, 10(6), 759-770.
2. Hailfinger, S.; Jaworski, M.; Braeuning, A.; Buchmann, A.; Schwarz, M. Zonal gene expression in murine liver: Lessons from tumors. Hepatology, 2006, 43(3), 407-414.
3. Sekine, S.; Lan, B.Y.A.; Bedolli, M.; Feng, S.; Hebrok, M. Liver-specific loss of catenin blocks glutamine synthetis pathway activity and cytochrome P450 expression in mice. Hepatology, 2006, 43(4), 817-825.
4. Braeuning, A.; Ittrich, C.; Kohle, C.; Buchmann, A.; Schwarz, M. Zonal gene expression in mouse liver resembles expression patterns of Ha-ras and beta-catenin mutated hepatomas. Drug Metab. Dispos., 2007, 35(4), 503-507.
5. Braeuning, A.; Menzel, M.; Kleinschnitz, E. M.; Harada, N.; Tamai, Y.; Kohle, C.; Buchmann, A.; Schwarz, M. Serum components and activated Ha-ras antagonize expression of perivenous marker genes stimulated by beta-catenin signaling in mouse hepatocytes. FEBS J., 2007, 274(18), 4766-4777.
6. Tan, X.; Behari, J.; Cieply, B.; Michalopoulos, G.K.; Monga, S.P. Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology, 2006, 131(5), 1561-1572.
7. Raman, M.; Chen, W.; Cobb, M.H. Differential regulation and properties of MAPKs. Oncogene, 2007, 26(22), 3100-3112.
8. Dhanasekaran, D. N.; Johnson, G. L. MAPKs: function, regulation, role in cancer and therapeutic targeting. Oncogene, 2007, 26(22), 3097-3099.
9. Willert, K.; Nusse, R. Beta-catenin: a key mediator of Wnt signaling. Curr. Opin. Genet. Dev., 1998, 8(1), 95-102.
10. Lustig, B.; Behrens, J. The Wnt signaling pathway and its role in tumor development. J. Cancer Res. Clin. Oncol., 2003, 129(4), 199-221.
11. Mead, J.E.; Fausto, N. Transforming growth factor alpha may be a physiological regulator of liver regeneration by means of an autocrine mechanism. Proc. Natl. Acad. Sci. USA, 1989, 86(5), 1558-1562.
12. Ching, K.Z.; Tenney, K.A.; Chen, J.; Morgan, E.T. Suppression of constitutive cytochrome P450 gene expression by epidermal growth factor receptor ligands in cultured rat hepatocytes. Drug Metab. Dispos., 1996, 24(5), 542-546.
13. Garcia, M.C.; Thangavel, C.; Shapiro, B.H. Epidermal growth factor regulation of female-dependent CYP2A1 and CYP2C12 in primary rat hepatocyte culture. Drug Metab. Dispos., 2001, 29(2), 111-120.
14. Aubrecht, J.; Hirsch-Ernst, K.I.; Becker-Rabbenstein, V.; Kahl, G.F.; Taniguchi, H.; Hohne, M.W. Induction of cytochrome P-4502B1-related mouse cytochrome P-450 and regulation of its expression by epidermal growth factor/transforming growth factor alpha in primary hepatocyte culture. Biochem. Pharmacol., 1995, 50(6), 781-785.
15. Greuet, J.; Pichard, L.; Ourlin, J.C.; Bonfils, C.; Domergue, J.; Le Treut, P.; Maurel, P. Effect of cell density and epidermal growth factor on the inducible expression of CYP3A and CYP1A genes in human hepatocytes in primary culture. Hepatology, 1997, 25(5), 1166-1175.
16. De Smet, K.; Loyer, P.; Gilot, D.; Vercruysse, A.; Rogiers, V.; Guguen-Guillouzo, C. Effects of epidermal growth factor on CYP inducibility by xenobiotics, DNA replication, and caspase activations in collagen I gel sandwich cultures of rat hepatocytes. Biochem. Pharmacol., 2001, 61(10), 1293-1303.
17. Tinel, M.; Berson, A.; Elkahwaji, J.; Cresteil, T.; Beaune, P.; Pessayre, D. Downregulation of cytochromes P450 in growth-stimulated rat hepatocytes: role of c-Myc induction and impaired C/EBP binding to DNA. J. Hepatol., 2003, 39(2), 171-178.
18. Henkens, T.; Vinken, M.; Vanhaecke, T.; Rogiers, V. Modulation of CYP1A1 and CYP2B1 expression upon cell cycle progression in cultures of primary rat hepatocytes. Toxicol. In Vitro, 2007, 21(7), 1253-1257.
19. Guo, M.; Joiakim, A.; Dudley, D.T.; Reiners, J.J. Suppression of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated CYP1A1 and CYP1B1 induction by 12-O-tetradecanoylphorbol-13-acetate: role of transforming growth factor beta and mitogen-activated protein kinases. Biochem. Pharmacol., 2001, 62(11), 1449-1457.
20. Larsen, M.C.; Brake, P.B.; Pollenz, R.S.; Jefcoate, C.R. Linked expression of Ah receptor, ARNT, CYP1A1, and CYP1B1 in rat mammary epithelia, in vitro, is each substantially elevated by specific extracellular matrix interactions that precede branching morphogenesis. Toxicol. Sci., 2004, 82(1), 46-61.
21. Andrieux, L.; Langouet, S.; Fautrel, A.; Ezan, F.; Krauser, J.A.; Savouret, J.F.; Guengerich, F.P.; Baffet, G.; Guillouzo, A. Aryl hydrocarbon receptor activation and cytochrome P450 1A induction by the mitogen-activated protein kinase inhibitor U0126 in hepatocytes. Mol. Pharmacol., 2004, 65(4), 934-943.
22. Chen, S.; Operana, T.; Bonzo, J.; Nguyen, N.; Tukey, R.H. ERK kinase inhibition stabilizes the aryl hydrocarbon receptor: implications for transcriptional activation and protein degradation. J. Biol. Chem., 2005, 280(6), 4350-4359.
23. Koike, C.; Moore, R.; Negishi, M. Extracellular signal-regulated kinase is an endogenous signal retaining the nuclear constitutive active/ androstane receptor (CAR) in the cytoplasm of mouse primary hepatocytes. Mol. Pharmacol., 2007, 71(5), 1217-1221.
24. Bauer, D.; Wolfram, N.; Kahl, G.F.; Hirsch-Ernst, K.I. Transcriptional regulation of CYP2B1 induction in primary rat hepatocyte cultures: repression by epidermal growth factor is mediated via a distal enhancer region. Mol. Pharmacol., 2004, 65(1), 172-180.
25. Donato, M.T.; Gomez-Lechon, M.J.; Jover, R.; Nakamura, T.; Castell, J.V. Human hepatocyte growth factor down-regulates the expression of cytochrome P450 isozymes in human hepatocytes in primary culture. J. Pharmacol. Exp. Ther., 1998, 284(2), 760-767.
26. Grunnet, N.; Tygstrup, N.; Dich, J. Autoprotection against acetaminophen toxicity in cultured rat hepatocytes: the effect of pretreatment and growth factors. Pharmacol. Toxicol., 2003, 93(3), 135-141.
27. Kim, S.K.; Novak, R.F. The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression. Pharmacol. Ther., 2007, 113(1), 88-120.
28. Oinonen, T.; Lindros, K.O. Zonation of hepatic cytochrome P-450 expression and regulation. Biochem. J., 1998, 329(Pt 1), 17-35.
29. Lindros, K.O. Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver. Gen. Pharmacol., 1997, 28(2), 191-196.
30. Oinonen, T.; Mode, A.; Lobie, P.E.; Lindros, K.O. Zonation of cytochrome P450 enzyme expression in rat liver. Isozyme-specific regulation by pituitary dependent hormones. Biochem. Pharmacol., 1996, 51(10), 1379-1387.
31. Mode, A.; Ahlgren, R.; Lahuna, O.; Gustafsson, J.A. Gender differences in rat hepatic CYP2C gene expression-regulation by growth hormone. Growth Horm. IGF Res., 1998, 8(Suppl B), 61-67.
32. Winston, L.A.; Hunter, T. JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone. J. Biol. Chem., 1995, 270(52), 30837-30840.
33. Winston, L.A.; Bertics, P.J. Growth hormone stimulates the tyrosine phosphorylation of 42- and 45-kDa ERK-related proteins. J. Biol. Chem., 1992, 267(7), 4747-4751.
34. Campbell, G.S.; Pang, L.; Miyasaka, T.; Saltiel, A.R.; Carter-Su, C. Stimulation by growth hormone of MAP kinase activity in 3T3-F442A fibroblasts. J. Biol. Chem., 1992, 267(9), 6074-6080.
35. Wiwi, C.A.; Waxman, D.J. Role of hepatocyte nuclear factors in growth hormone-regulated, sexually dimorphic expression of liver cytochromes P450. Growth Factors, 2004, 22(2), 79-88.
36. Gonzalez, F.J.; Lee, Y.H. Constitutive expression of hepatic cytochrome P450 genes. FASEB J., 1996, 10(10), 1112-1117.
37. Waxman, D.J.; O'Connor, C. Growth hormone regulation of sex-dependent liver gene expression. Mol. Endocrinol., 2006, 20(11), 2613-2629.
38. Mode, A.; Gustafsson, J.A. Sex and the liver - a journey through five decades. Drug Metab. Rev., 2006, 38(1-2), 197-207.
39. Thangavel, C.; Shapiro, B.H. Inherent sexually dimorphic expression of hepatic cyp2c12 correlated with repressed activation of growth hormone-regulated signal transduction in male rats. Drug Metab. Dispos., 2008, 36(9), 1884-1895.
40. Verma, A.S.; Dhir, R.N.; Shapiro, B.H. Inadequacy of the Janus kinase 2/ signal transducer and activator of transcription signal transduction pathway to mediate episodic growth hormone-dependent regulation of hepatic CYP2C11. Mol. Pharmacol., 2005, 67(3), 891-901.
41. Saitoh, A.; Kimura, M.; Takahashi, R.; Yokoyama, M.; Nomura, T.; Izawa, M.; Sekiya, T.; Nishimura, S.; Katsuki, M. Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene, 1990, 5(8), 1195-1200.
42. Katsutani, N.; Sekido, T.; Aoki, T.; Sagami, F. Hepatic drug metabolizing enzymes induced by clofibrate in rasH2 mice. Toxicol. Lett., 2000, 115(3), 223-229.
43. Ohnishi, Y.; Arai, T.; Koshirakawa, M.; Horii, N.; Nakajo, S.; Urano, K.; Usui, T.; Tamaoki, N.; Ueyama, Y. Induction of drug metabolism-related enzymes by methylcholanthrene and phenobarbital in transgenic mice carrying human prototype c-Ha-ras gene and their wild type littermates. Exp. Anim., 2001, 50(1), 33-39.
44. Ariyoshi, N.; Imaoka, S.; Nakayama, K.; Takahashi, Y.; Fujita, K.; Funae, Y.; Kamataki, T. Comparison of the levels of enzymes involved in drug metabolism between transgenic or gene-knockout and the parental mice. Toxicol. Pathol., 2001, 29(Suppl), 161-172.
45. Leder, A.; Kuo, A.; Cardiff, R.D.; Sinn, E.; Leder, P. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc. Natl. Acad. Sci. USA, 1990, 87(23), 9178-9182.
46. Sanders, J.M.; Burka, L.T.; Chanas, B.; Matthews, H.B. Comparative xenobiotic metabolism between Tg.AC and p53+/- genetically altered mice and their respective wild types. Toxicol. Sci., 2001, 61(1), 54-61.
47. Harada, N.; Oshima, H.; Katoh, M.; Tamai, Y.; Oshima, M.;Taketo, M.M. Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res., 2004, 64(1), 48-54.
48. Harada, N.; Miyoshi, H.; Murai, N.; Oshima, H.; Tamai, Y.; Oshima, M.; Taketo, M.M. Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Res., 2002, 62(7), 1971-1977.
49. Kakizaki, S.; Yamazaki, Y.; Kosone, T.; Horiguchi, N.; Sohara, N.; Sato, K.; Takagi, H.; Yoshinari, K.; Mori, M. Gene expression profiles of drug-metabolizing enzymes and transporters with an overexpression of hepatocyte growth factor. Liver Int., 2007, 27(1), 109-119.
50. Takami, T.; Kaposi-Novak, P.; Uchida, K.; Gomez-Quiroz, L.E.; Conner, E.A.; Factor, V.M.; Thorgeirsson, S.S. Loss of hepatocyte growth factor/ c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res., 2007, 67(20), 9844-9851.
51. Aydinlik, H.; Nguyen, T.D.; Moennikes, O.; Buchmann, A.; Schwarz, M. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors. Oncogene, 2001, 20(53), 7812-7816.
52. Stahl, S.; Ittrich, C.; Marx-Stoelting, P.; Kohle, C.; Altug-Teber, O.; Riess, O.; Bonin, M.; Jobst, J.; Kaiser, S.; Buchmann, A.; Schwarz, M. Genotype-phenotype relationships in hepatocellular tumors from mice and man. Hepatology, 2005, 42(2), 353-361.
53. Jaworski, M.; Ittrich, C.; Hailfinger, S.; Bonin, M.; Buchmann, A.; Schwarz, M.; Kohle, C. Global gene expression in Ha-ras and B-raf mutated mouse liver tumors. Int. J. Cancer, 2007, 121(6), 1382-1385.
54. Loeppen, S.; Koehle, C.; Buchmann, A.; Schwarz, M. A beta-catenin-dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors. Carcinogenesis, 2005, 26(1), 239-248.
55. Reiners, J.J., Jr.; Jones, C.L.; Hong, N.; Clift, R.E.; Elferink, C. Downregulation of aryl hydrocarbon receptor function and cytochrome P450 1A1 induction by expression of Ha-ras oncogenes. Mol. Carcinog., 1997, 19(2), 91-100.
56. Reiners, J.J., Jr.; Jones, C.L.; Hong, N.; Myrand, S.P. Differential induction of Cyp1a1, Cyp1b1, Ahd4, and Nmo1 in murine skin tumors and adjacent normal epidermis by ligands of the aryl hydrocarbon receptor. Mol. Carcinog., 1998, 21(2), 135-146.
57. Quintanilla, M.; Brown, K.; Ramsden, M.; Balmain, A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature, 1986, 322(6074), 78-80.
58. LaFramboise, W.A.; Bombach, K.L.; Dhir, R.J.; Muha, N.; Cullen, R.F.; Pogozelski, A.R.; Turk, D.; George, J.D.; Guthrie, R.D.; Magovern, J.A. Molecular dynamics of the compensatory response to myocardial infarct. J. Mol. Cell. Cardiol., 2005, 38(1), 103-117.
59. Morgan, E.T. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab. Dispos., 2001, 29(3), 207-212.
60. Jover, R.; Bort, R.; Gomez-Lechon, M.J.; Castell, J.V. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J., 2002, 16(13), 1799-1801.
61. Tinel, M.; Elkahwaji, J.; Robin, M.A.; Fardel, N.; Descatoire, V.; Haouzi, D.; Berson, A.; Pessayre, D. Interleukin-2 overexpresses c-myc and down-regulates cytochrome P-450 in rat hepatocytes. J. Pharmacol. Exp. Ther., 1999, 289(2), 649-655.
62. Donato, M.T.; Guillen, M.I.; Jover, R.; Castell, J.V.; Gomez-Lechon, M.J. Nitric oxide-mediated inhibition of cytochrome P450 by interferon-gamma in human hepatocytes. J. Pharmacol. Exp. Ther., 1997, 281(1), 484-490.
63. Stadler, J.; Trockfeld, J.; Schmalix, W.A.; Brill, T.; Siewert, J.R.; Greim, H.; Doehmer, J. Inhibition of cytochromes P4501A by nitric oxide. Proc. Natl. Acad. Sci. USA, 1994, 91(9), 3559-3563.
64. De Waziers, I.; Garlatti, M.; Bouguet, J.; Beaune, P.H.; Barouki, R. Insulin down-regulates cytochrome P450 2B and 2E expression at the post-transcriptional level in the rat hepatoma cell line. Mol. Pharmacol., 1995, 47(3), 474-479.
65. Woodcroft, K.J.; Hafner, M.S.; Novak, R.F. Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology, 2002, 35(2), 263-273.
66. Woodcroft, K.J.; Novak, R.F. Insulin effects on CYP2E1, 2B, 3A, and 4A expression in primary cultured rat hepatocytes. Chem. Biol. Interact., 1997, 107(1-2), 75-91.
67. Woodcroft, K.J.; Novak, R.F. Insulin differentially affects xenobiotic-enhanced, cytochrome P-450 (CYP)2E1, CYP2B, CYP3A, and CYP4A expression in primary cultured rat hepatocytes. J. Pharmacol. Exp. Ther., 1999, 289(2), 1121-1127.
68. Woodcroft, K.J.; Novak, R.F. The role of phosphatidylinositol 3-kinase, Src kinase, and protein kinase A signaling pathways in insulin and glucagon regulation of CYP2E1 expression. Biochem. Biophys. Res. Commun., 1999, 266(2), 304-307.
69. Sidhu, J.S.; Liu, F.; Boyle, S.M.; Omiecinski, C.J. PI3K inhibitors reverse the suppressive actions of insulin on CYP2E1 expression by activating stress-response pathways in primary rat hepatocytes. Mol. Pharmacol., 2001, 59(5), 1138-1146.
70. Tamaki, H.; Sakuma, T.; Uchida, Y.; Jaruchotikamol, A.; Nemoto, N. Activation of CYP1A1 gene expression during primary culture of mouse hepatocytes. Toxicology, 2005, 216(2-3), 224-231.
71. Hohne, M.; Becker-Rabbenstein, V.; Kahl, G.F.; Taniguchi, H. Regulation of cytochrome P-450 CYPIA1 gene expression and proto-oncogene expression by growth factors in primary hepatocytes. FEBS Lett., 1990, 273(1-2), 219-222.
72. Jungermann, K. Zonation of metabolism and gene expression in liver. Histochem. Cell Biol., 1995, 103(2), 81-91.
73. Jungermann, K.; Katz, N. Functional specialization of different hepatocyte populations. Physiol. Rev., 1989, 69(3), 708-764.
74. Jungermann, K.; Kietzmann, T. Zonation of parenchymal and nonparenchymal metabolism in liver. Annu. Rev. Nutr., 1996, 16, 179-203.
75. Lemaigre, F.P.; Rousseau, G.G. Transcriptional control of genes that regulate glycolysis and gluconeogenesis in adult liver. Biochem. J., 1994, 303(Pt 1), 1-14.
76. Gebhardt, R. Metabolic zonation of the liver: regulation and implications for liver function. Pharmacol. Ther., 1992, 53(3), 275-354.
77. Liddle, C.; Murray, M.; Farrell, G.C. Effect of liver regeneration on hepatic cytochrome P450 isozymes and serum sex steroids in the male rat. Gastroenterology, 1989, 96(3), 864-872.
78. Ronis, M.J.; Lumpkin, C.K.; Thomas, P.E.; Ingelman-Sundberg, M.; Badger, T.M. The microsomal monooxygenase system of regenerating liver. An examination of the role of estradiol in the demasculinization of drug metabolism produced by 2/3 partial hepatectomy. Biochem. Pharmacol., 1992, 43(3), 567-573.
79. Marie, I.J.; Dalet, C.; Blanchard, J.M.; Astre, C.; Szawlowski, A.; Saint Aubert, B.; Joyeux, H.; Maurel, P. Inhibition of cytochrome P-450p (P450IIIA1) gene expression during liver regeneration from two-thirds hepatectomy in the rat. Biochem. Pharmacol., 1988, 37(18), 3515-3521.
80. Fausto, N. Liver regeneration. J. Hepatol., 2000, 32(Suppl 1), 19-31.
81. Wu, H.; Wade, M.; Krall, L.; Grisham, J.; Xiong, Y.; Van Dyke, T. Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration. Genes Dev., 1996, 10(3), 245-260.
82. Lee, Y.H.; Yano, M.; Liu, S.Y.; Matsunaga, E.; Johnson, P.F.; Gonzalez, F.J. A novel cis-acting element controlling the rat CYP2D5 gene and requiring cooperativity between C/EBP beta and an Sp1 factor. Mol. Cell. Biol., 1994, 14(2), 1383-1394.
83. Jover, R.; Bort, R.; Gomez-Lechon, M.J.; Castell, J.V. Reexpression of C/ EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells. FEBS Lett., 1998, 431(2), 227-230.
84. Ourlin, J.C.; Jounaidi, Y.; Maurel, P.; Vilarem, M.J. Role of the liver-enriched transcription factors C/EBP alpha and DBP in the expression of human CYP3A4 and CYP3A7. J. Hepatol., 1997, 26(Suppl 2), 54-62.
85. Rodrigues, E.; Vilarem, M.J.; Ribeiro, V.; Maurel, P.; Lechner, M.C. Two CCAAT/enhancer binding protein sites in the cytochrome P4503A1 locus. Potential role in the glucocorticoid response. Eur. J. Biochem., 2003, 270(3), 556-564.
86. Block, G.D.; Locker, J.; Bowen, W.C.; Petersen, B.E.; Katyal, S.; Strom, S.C.; Riley, T.; Howard, T.A.; Michalopoulos, G.K. Population expansion, clonal growth, and specific differentiation patterns in primary cultures of hepatocytes induced by HGF/SF, EGF and TGF *= 224 in a chemically defined (HGM) medium. J. Cell Biol., 1996, 132(6), 1133-1149.
87. Elkahwaji, J.; Robin, M.A.; Berson, A.; Tinel, M.; Letteron, P.; Labbe, G.; Beaune, P.; Elias, D.; Rougier, P.; Escudier, B.; Duvillard, P.; Pessayre, D. Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem. Pharmacol., 1999, 57(8), 951-954.
88. Tronche, F.; Ringeisen, F.; Blumenfeld, M.; Yaniv, M.; Pontoglio, M. Analysis of the distribution of binding sites for a tissue-specific transcription factor in the vertebrate genome. J. Mol. Biol., 1997, 266(2), 231-245.
89. Park, S.H.; Waxman, D.J. Inhibitory cross-talk between STAT5b and liver nuclear factor HNF3beta: impact on the regulation of growth hormone pulse-stimulated, male-specific liver cytochrome P-450 gene expression. J. Biol. Chem., 2001, 276(46), 43031-43039.
90. Ogino, M.; Nagata, K.; Miyata, M.; Yamazoe, Y. Hepatocyte nuclear factor 4-mediated activation of rat CYP3A1 gene and its modes of modulation by apolipoprotein AI regulatory protein I and v-ErbA-related protein 3. Arch. Biochem. Biophys., 1999, 362(1), 32-37.
91. Cheung, C.; Akiyama, T.E.; Kudo, G.; Gonzalez, F.J. Hepatic expression of cytochrome P450s in hepatocyte nuclear factor 1-alpha (HNF1alpha)-deficient mice. Biochem. Pharmacol., 2003, 66(10), 2011-2020.
92. Jover, R.; Bort, R.; Gomez-Lechon, M.J.; Castell, J.V. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology, 2001, 33(3), 668-675.
93. Tirona, R.G.; Lee, W.; Leake, B.F.; Lan, L.B.; Cline, C.B.; Lamba, V.; Parviz, F.; Duncan, S.A.; Inoue, Y.; Gonzalez, F.J.; Schuetz, E.G.; Kim, R.B. The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat. Med., 2003, 9(2), 220-224.
94. Schrem, H.; Klempnauer, J.;Borlak, J. Liver-enriched transcription factors in liver function and development. Part I: the hepatocyte nuclear factor network and liver-specific gene expression. Pharmacol. Rev., 2002, 54(1), 129-158.
95. Schrem, H.; Klempnauer, J.; Borlak, J. Liver-enriched transcription factors in liver function and development. Part II: the C/EBPs and D site-binding protein in cell cycle control, carcinogenesis, circadian gene regulation, liver regeneration, apoptosis, and liver-specific gene regulation. Pharmacol. Rev., 2004, 56(2), 291-330.
96. Tago, K.; Nakamura, T.; Nishita, M.; Hyodo, J.; Nagai, S.; Murata, Y.; Adachi, S.; Ohwada, S.; Morishita, Y.; Shibuya, H.; Akiyama, T. Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein. Genes Dev., 2000, 14(14), 1741-1749.
97. Hsu, T.; Trojanowska, M.; Watson, D.K. Ets proteins in biological control and cancer. J. Cell. Biochem., 2004, 91(5), 896-903.
98. Threadgill, D.W. Down's syndrome: paradox of a tumour repressor. Nature, 2008, 451(7174), 21-22.
99. Gebhardt, R.; Marti, U. Heterogeneous distribution of the epidermal growth factor receptor in rat liver parenchyma. Prog. Histochem. Cytochem., 1992, 26(1-4), 164-168.
100. Marti, U.; Gebhardt, R. Acinar heterogeneity of the epidermal growth factor receptor in the liver of male rats. Eur. J. Cell Biol., 1991, 55(1), 158-164.
101. Chabot, J.G.; Walker, P.; Pelletier, G. Distribution of epidermal growth factor binding sites in the adult rat liver. Am. J. Physiol., 1986, 250(6 Pt 1), G760-764.
102. Loeppen, S.; Schneider, D.; Gaunitz, F.; Gebhardt, R.; Kurek, R.; Buchmann, A.; Schwarz, M. Overexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital. Cancer Res., 2002, 62(20), 5685-5688.
103. Strathmann, J.; Paal, K.; Ittrich, C.; Krause, E.; Appel, K.E.; Glauert, H.P.; Buchmann, A.; Schwarz, M. Proteome analysis of chemically induced mouse liver tumors with different genotype. Proteomics, 2007, 7(18), 3318-3331.
104. Bock, K.W. Aryl hydrocarbon or dioxin receptor: biologic and toxic responses. Rev. Physiol. Biochem. Pharmacol., 1994, 125, 1-42.
105. Corcos, L.; Lagadic-Gossmann, D. Gene induction by Phenobarbital: an update on an old question that receives key novel answers. Pharmacol. Toxicol., 2001, 89(3), 113-122.
106. Swales, K.; Negishi, M. CAR, driving into the future. Mol. Endocrinol., 2004, 18(7), 1589-1598.
107. Tompkins, L.M.; Wallace, A.D. Mechanisms of cytochrome P450 induction. J. Biochem. Mol. Toxicol., 2007, 21(4), 176-181.
108. Tan, Z.; Chang, X.; Puga, A.; Xia, Y. Activation of mitogen-activated protein kinases (MAPKs) by aromatic hydrocarbons: role in the regulation of aryl hydrocarbon receptor (AHR) function. Biochem. Pharmacol., 2002, 64(5-6), 771-780.
109. Tan, Z.; Huang, M.; Puga, A.; Xia, Y. A critical role for MAP kinases in the control of Ah receptor complex activity. Toxicol. Sci., 2004, 82(1), 80-87.
110. Tsukumo, S.; Iwata, M.; Tohyama, C.; Nohara, K. Skewed differentiation of thymocytes toward CD8 T cells by 2,3,7,8-tetrachlorodibenzo- p-dioxin requires activation of the extracellular signal-related kinase pathway. Arch. Toxicol., 2002, 76(5-6), 335-343.
111. Reiners, J.J., Jr.; Lee, J.Y.; Clift, R.E.; Dudley, D.T.; Myrand, S.P. PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase. Mol. Pharmacol., 1998, 53(3), 438-445.
112. Tang, C.; Chiba, M.; Nishime, J.; Hochman, J.H.; Chen, I.; Williams, T.M.; Lin, J.H. Comparison of imidazole- and 2-methyl imidazole-containing farnesyl-protein transferase inhibitors: interaction with and metabolism by rat hepatic cytochrome P450s. Drug Metab. Dispos., 2000, 28(6), 680-686.
113. Joiakim, A.; Mathieu, P.A.; Palermo, C.; Gasiewicz, T.A.; Reiners, J.J., Jr. The Jun N-terminal kinase inhibitor SP600125 is a ligand and antagonist of the aryl hydrocarbon receptor. Drug Metab. Dispos., 2003, 31(11), 1279-1282.
114. Dvorak, Z.; Vrzal, R.; Henklova, P.; Jancova, P.; Anzenbacherova, E.; Maurel, P.; Svecova, L.; Pavek, P.; Ehrmann, J.; Havlik, R.; Bednar, P.; Lemr, K.; Ulrichova, J. JNK inhibitor SP600125 is a partial agonist of human aryl hydrocarbon receptor and induces CYP1A1 and CYP1A2 genes in primary human hepatocytes. Biochem. Pharmacol., 2008, 75(2), 580-588.
115. Guo, M.; Joiakim, A.; Reiners, J.J., Jr. Suppression of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated aryl hydrocarbon receptor transformation and CYP1A1 induction by the phosphatidylinositol 3-kinase inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). Biochem. Pharmacol., 2000, 60(5), 635-642.
116. Schafer, M.W.; Madhukar, B.V.; Swanson, H.I.; Tullis, K.; Denison, M.S. Protein kinase C is not involved in Ah receptor transformation and DNA binding. Arch. Biochem. Biophys., 1993, 307(2), 267-271.
117. Shibazaki, M.; Takeuchi, T.; Ahmed, S.; Kikuchi, H. Suppression by p38 MAP kinase inhibitors (pyridinyl imidazole compounds) of Ah receptor target gene activation by 2,3,7,8-tetrachlorodibenzo-pdioxin and the possible mechanism. J. Biol. Chem., 2004, 279(5), 3869-3876.
118. Joannard, F.; Rissel, M.; Gilot, D.; Anderson, A.; Orfila-Lefeuvre, L.; Guillouzo, A.; Atfi, A.; Lagadic-Gossmann, D. Role for mitogen-activated protein kinases in phenobarbital-induced expression of cytochrome P450 2B in primary cultures of rat hepatocytes. Toxicol. Lett., 2006, 161(1), 61-72.
119. Soule, H.D.; Maloney, T.M.; Wolman, S.R.; Peterson, W.D., Jr.; Brenz, R.; McGrath, C.M.; Russo, J.; Pauley, R.J.; Jones, R.F.; Brooks, S.C. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res., 1990, 50(18), 6075-6086.
120. Basolo, F.; Elliott, J.; Tait, L.; Chen, X.Q.; Maloney, T.; Russo, I.H.; Pauley, R.; Momiki, S.; Caamano, J.; Klein-Szanto, A.J.; Koszalka, M.; Russo, J. Transformation of human breast epithelial cells by c-Ha-ras oncogene. Mol. Carcinog., 1991, 4(1), 25-35.
121. Broccardo, C.J.; Billings, R.E.; Andersen, M.E.; Hanneman, W.H. Probing the control elements of the CYP1A1 switching module in H4IIE hepatoma cells. Toxicol. Sci., 2005, 88(1), 82-94.
122. Chang, C.Y.; Puga, A. Constitutive activation of the aromatic hydrocarbon receptor. Mol. Cell. Biol., 1998, 18(1), 525-535.
123. Yim, S.; Oh, M.; Choi, S.M.; Park, H. Inhibition of the MEK-1/p42 MAP kinase reduces aryl hydrocarbon receptor-DNA interactions. Biochem. Biophys. Res. Commun., 2004, 322(1), 9-16.
124. Greenhalgh, D.A.; Rothnagel, J.A.; Quintanilla, M.I.; Orengo, C.C.; Gagne, T.A.; Bundman, D.S.; Longley, M.A.; Roop, D.R. Induction of epidermal hyperplasia, hyperkeratosis, and papillomas in transgenic mice by a targeted v-Ha-ras oncogene. Mol. Carcinog., 1993, 7(2), 99-110.
125. Abbott, B.D.; Buckalew, A.R.; DeVito, M.J.; Ross, D.; Bryant, P.L.; Schmid, J.E. EGF and TGF-alpha expression influence the developmental toxicity of TCDD: dose response and AhR phenotype in EGF, TGF-alpha, and EGF + TGF-alpha knockout mice. Toxicol. Sci., 2003, 71(1), 84-95.
126. Kietzmann, T.; Hirsch-Ernst, K.I.; Kahl, G.F.; Jungermann, K. Mimicry in primary rat hepatocyte cultures of the in vivo perivenous induction by phenobarbital of cytochrome P-450 2B1 mRNA: role of epidermal growth factor and perivenous oxygen tension. Mol. Pharmacol., 1999, 56(1), 46-53.
127. Kawamura, A.; Yoshida, Y.; Kimura, N.; Oda, H.; Kakinuma, A. Phosphorylation/Dephosphorylation steps are crucial for the induction of CYP2B1 and CYP2B2 gene expression by phenobarbital. Biochem. Biophys. Res. Commun., 1999, 264(2), 530-536.
128. Joannard, F.; Galisteo, M.; Corcos, L.; Guillouzo, A.; Lagadic-Gossmann, D. Regulation of phenobarbital-induction of CYP2B and CYP3A genes in rat cultured hepatocytes: involvement of several serine/threonine protein kinases and phosphatases. Cell Biol. Toxicol., 2000, 16(5), 325-337.
129. Osabe, M.; Sugatani, J.; Takemura, A.; Yamazaki, Y.; Ikari, A.; Kitamura, N.; Negishi, M.; Miwa, M. Expression of CAR in SW480 and HepG2 cells during G1 is associated with cell proliferation. Biochem. Biophys. Res. Commun., 2008, 369(4), 1027-1033.
130. Jones, C.L.; Reiners, J.J., Jr. Differentiation status of cultured murine keratinocytes modulates induction of genes responsive to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Arch. Biochem. Biophys., 1997, 347(2), 163-173.
131. Cho, Y.C.; Zheng, W.; Jefcoate, C.R. Disruption of cell-cell contact maximally but transiently activates AhR-mediated transcription in 10T1/2 fibroblasts. Toxicol. Appl. Pharmacol., 2004, 199(3), 220-238.
132. Minsavage, G.D.; Vorojeikina, D.P.; Gasiewicz, T.A. Mutational analysis of the mouse aryl hydrocarbon receptor tyrosine residues necessary for recognition of dioxin response elements. Arch. Biochem. Biophys., 2003, 412(1), 95-105.
133. Henklova, P.; Vrzal, R.; Ulrichova, J.; Dvorak, Z. Role of mitogen-activated protein kinases in aryl hydrocarbon receptor signaling. Chem. Biol. Interact., 2008, 172(2), 93-104.
134. Yamamoto, Y.; Kawamoto, T.; Negishi, M. The role of the nuclear receptor CAR as a coordinate regulator of hepatic gene expression in defense against chemical toxicity. Arch. Biochem. Biophys., 2003, 409(1), 207-211.
135. Rencurel, F.; Foretz, M.; Kaufmann, M.R.; Stroka, D.; Looser, R.; Leclerc, I.; da Silva Xavier, G.; Rutter, G.A.; Viollet, B.; Meyer, U.A. Stimulation of AMP-activated protein kinase is essential for the induction of drug metabolizing enzymes by phenobarbital in human and mouse liver. Mol. Pharmacol., 2006, 70(6), 1925-1934.
136. Rencurel, F.; Stenhouse, A.; Hawley, S.A.; Friedberg, T.; Hardie, D.G.; Sutherland, C.; Wolf, C.R. AMP-activated protein kinase mediates phenobarbital induction of CYP2B gene expression in hepatocytes and a newly derived human hepatoma cell line. J. Biol. Chem., 2005, 280(6), 4367-4373.
137. Braeuning, A.; Ittrich, C.; Kohle, C.; Hailfinger, S.; Bonin, M.; Buchmann, A.; Schwarz, M. Differential gene expression in periportal and perivenous mouse hepatocytes. FEBS J., 2006, 273(22), 5051-5061.
138. Hassett, C.; Luchtel, D.L.; Omiecinski, C.J. Hepatic expression of rat P450 mRNA assessed by in situ hybridization to oligomer probes. DNA, 1989, 8(1), 29-37.
139. Brieva, T.A.; Moghe, P.V. Exogenous cadherin microdisplay can interfere with endogenous signaling and reprogram gene expression in cultured hepatocytes. Biotechnol. Bioeng., 2004, 85(3), 283-292.
140. Tan, X.; Apte, U.; Micsenyi, A.; Kotsagrelos, E.; Luo, J.H.; Ranganathan, S.; Monga, D.K.; Bell, A.; Michalopoulos, G.K.; Monga, S.P. Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology, 2005, 129(1), 285-302.
141. Sattar, A.; Hewer, A.; Phillips, D.H.; Campbell, F.C. Metabolic proficiency and benzo[a]pyrene DNA adduct formation in APCMin mouse adenomas and uninvolved mucosa. Carcinogenesis, 1999, 20(6), 1097-1101.
142. Chang, H.; Su, J.M.; Huang, C.C.; Liu, L.C.; Tsai, C.H.; Chou, M.C.; Lin, P. Using a combination of cytochrome P450 1B1 and beta-catenin for early diagnosis and prevention of colorectal cancer. Cancer Detect. Prev., 2005, 29(6), 562-569.
143. Chesire, D.R.; Dunn, T.A.; Ewing, C.M.; Luo, J.; Isaacs, W.B. Identification of aryl hydrocarbon receptor as a putative Wnt/ beta-catenin pathway target gene in prostate cancer cells. Cancer Res., 2004, 64(7), 2523-2533.
144. Yochum, G.S.; McWeeney, S.; Rajaraman, V.; Cleland, R.; Peters, S.; Goodman, R.H. Serial analysis of chromatin occupancy identifies beta-catenin target genes in colorectal carcinoma cells. Proc. Natl. Acad. Sci. USA, 2007, 104(9), 3324-3329.
145. Ueno, T.;Gonzalez, F.J. Transcriptional control of the rat hepatic CYP2E1 gene. Mol. Cell. Biol., 1990, 10(9), 4495-4505.
146. Sekine, S.; Gutierrez, P.J.; Lan, B.Y.; Feng, S.; Hebrok, M. Liver-specific loss of beta-catenin results in delayed hepatocyte proliferation after partial hepatectomy. Hepatology, 2007, 45(2), 361-368.